Fungal and Parasitic CNS Infections
Fungal and parasitic infections of the central nervous system represent a diverse group of diseases that are increasingly relevant in modern neurologic practice. The expanding population of immunocompromised individuals — from HIV/AIDS, organ transplantation, biologic therapies, and hematologic malignancies — has broadened the spectrum of patients at risk. Additionally, globalization and travel have brought endemic infections to non-endemic regions. These infections often present with insidious, non-specific neurologic symptoms, making early recognition challenging. Delays in diagnosis carry substantial morbidity and mortality. This review covers the major fungal and parasitic CNS infections with emphasis on clinical features, diagnostic strategies, and evidence-based treatment for the practicing neurologist.
Bottom Line
- Cryptococcal meningitis: The most common fungal CNS infection globally; predominantly in HIV (CD4 <100); diagnosed by CSF cryptococcal antigen (CrAg, >95% sensitive); treatment with amphotericin B + flucytosine induction followed by fluconazole consolidation/maintenance; aggressive ICP management with serial therapeutic LPs is critical for survival
- Coccidioidomycosis: Endemic to the southwestern US and Mexico; basilar meningitis with hydrocephalus; CSF complement-fixation antibody is diagnostic; fluconazole is first-line but often required lifelong for CNS disease
- Aspergillosis: Angioinvasive, producing hemorrhagic infarcts and brain abscess in severely immunocompromised (neutropenic) patients; voriconazole is first-line; high mortality (>50%)
- Mucormycosis: Rhinocerebral form classic in diabetic ketoacidosis; rapidly progressive sinusitis → orbital → cavernous sinus invasion; requires urgent surgical debridement + IV amphotericin B
- Neurocysticercosis: Most common cause of acquired epilepsy worldwide; Taenia solium; parenchymal cysts with scolex on imaging is pathognomonic; treatment depends on stage and location
- Cerebral malaria: Plasmodium falciparum; altered consciousness, seizures, retinal hemorrhages; IV artesunate is standard of care
- Key principle: Immunosuppressed patients with subacute neurologic decline require an expanded infectious differential that includes fungi and parasites; geographic and exposure history is essential
Fungal CNS Infections
Cryptococcal Meningitis
Cryptococcal meningitis, caused by Cryptococcus neoformans (and less commonly C. gattii), is the most common cause of fungal meningitis worldwide and a leading cause of death in HIV/AIDS in resource-limited settings. An estimated 220,000 cases occur annually, with approximately 180,000 deaths.
Risk Factors and Epidemiology
- HIV/AIDS: By far the most common risk factor; typically CD4 <100 cells/μL; may be the AIDS-presenting illness
- Organ transplantation: Second most common risk group; occurs months to years post-transplant during immunosuppressive therapy
- Sarcoidosis: T-cell dysfunction predisposes to cryptococcal infection even without immunosuppressive therapy
- Other immunosuppression: Chronic corticosteroid therapy, hematologic malignancies, idiopathic CD4 lymphopenia
- C. gattii distinction: Can infect immunocompetent individuals; endemic to Pacific Northwest, Australia, Papua New Guinea; often produces cryptococcomas (mass lesions); may be more treatment-refractory
Clinical Presentation
Cryptococcal meningitis presents subacutely over days to weeks with headache (the most common symptom), fever, malaise, and altered mental status. Neck stiffness is present in a minority (<30%). Cranial neuropathies (particularly CN VI from elevated ICP) and visual symptoms may occur. Papilledema reflects chronically elevated intracranial pressure. The insidious onset often leads to delayed presentation.
Elevated ICP in Cryptococcal Meningitis
- Critical feature: Elevated ICP is the primary cause of morbidity and mortality; opening pressure ≥25 cm H2O in >60% of patients at diagnosis
- Mechanism: Impaired CSF reabsorption by arachnoid granulations due to fungal polysaccharide blockage, not obstructive hydrocephalus
- Management: Serial therapeutic lumbar punctures are essential — remove CSF to achieve closing pressure <20 cm H2O or 50% reduction if very high; daily LPs may be needed initially
- If LPs insufficient: Lumbar drain or ventriculoperitoneal shunt may be required for refractory elevated ICP
- Failure to manage ICP: Single greatest predictor of poor outcome; more important than antifungal choice
Diagnosis
| Diagnostic Test | Sensitivity | Specificity | Notes |
|---|---|---|---|
| CSF CrAg (latex agglutination or LFA) | >95% | >95% | Rapid, highly reliable; lateral flow assay (LFA) is point-of-care; quantitative titer correlates with burden |
| Serum CrAg | ~95% in HIV | >95% | Can be used for screening; positive serum CrAg in HIV with CD4 <100 warrants LP even if asymptomatic |
| India ink stain | 60–80% | High | Visualizes encapsulated yeast; operator-dependent; less sensitive than CrAg |
| CSF culture | ~95% | 100% | Gold standard but takes 2–7 days; allows susceptibility testing and species identification |
| CSF profile | N/A | N/A | Elevated opening pressure, mild lymphocytic pleocytosis (may be minimal in HIV), elevated protein, low glucose |
Treatment of Cryptococcal Meningitis
| Phase | Regimen | Duration | Key Considerations |
|---|---|---|---|
| Induction | Amphotericin B deoxycholate (0.7–1 mg/kg/day) + flucytosine (100 mg/kg/day in 4 divided doses) | At least 2 weeks | Liposomal amphotericin preferred if available (less nephrotoxic); flucytosine improves CSF sterilization rate; monitor renal function, electrolytes, CBC |
| Consolidation | Fluconazole 400 mg/day | 8 weeks | Step-down after documented clinical improvement; CSF culture clearance ideally confirmed |
| Maintenance | Fluconazole 200 mg/day | ≥1 year (HIV); until immunosuppression reduced (transplant) | In HIV: discontinue after ≥1 year if CD4 >100 on ART for ≥3 months and undetectable viral load |
ART Timing in HIV-Cryptococcal Meningitis
- Critical principle: Delay ART initiation for 4–6 weeks after starting antifungal therapy
- Rationale: Early ART (within 1–2 weeks) increases mortality due to cryptococcal IRIS — demonstrated in the COAT trial
- Exception: This delay does NOT apply to other opportunistic infections where early ART is beneficial (e.g., Pneumocystis, toxoplasmosis)
Coccidioidomycosis (Coccidioides immitis/posadasii)
Coccidioides species are dimorphic fungi endemic to the southwestern United States (Arizona, Southern California, New Mexico, west Texas), Mexico, and parts of Central and South America. Primary infection occurs through inhalation of arthroconidia from soil. While most primary infections are self-limited respiratory illness, dissemination to the CNS occurs in <1% of infections but represents the most severe form of disease.
CNS Coccidioidomycosis — Clinical Features
- Basilar meningitis: The hallmark presentation; chronic meningitis with headache, low-grade fever, cranial neuropathies (especially CN VI, VII), and altered mental status over weeks to months
- Hydrocephalus: Communicating hydrocephalus from basilar meningeal inflammation and impaired CSF reabsorption; often requires VP shunt
- Vasculitis: Involvement of basilar meningeal arteries can produce ischemic strokes and lacunar infarcts
- CNS granulomas: Parenchymal mass lesions (coccidioidomas) can mimic tumors; surgical biopsy may be needed
- Spinal arachnoiditis: Meningeal inflammation can extend to the spinal cord, causing myelopathy and radiculopathy
- Risk factors for dissemination: Filipino and African American descent, immunosuppression (HIV, transplant, corticosteroids), pregnancy (third trimester), male sex
Diagnosis and Treatment of CNS Coccidioidomycosis
CSF shows lymphocytic pleocytosis, elevated protein, low glucose, and frequently eosinophils (a helpful clue). CSF complement-fixation (CF) antibody is the key diagnostic test — sensitivity ~75% for meningitis, with titer correlating to disease burden. Serum CF antibody is also useful. CSF culture is positive in <30% of cases. MRI shows basilar meningeal enhancement, hydrocephalus, and occasionally parenchymal lesions or infarcts.
Treatment is fluconazole 400–800 mg/day (first-line) or itraconazole 400 mg/day. CNS coccidioidomycosis requires lifelong antifungal therapy due to unacceptably high relapse rates with discontinuation. Intrathecal amphotericin B is reserved for refractory cases. Hydrocephalus frequently requires VP shunting.
Aspergillosis
Invasive CNS aspergillosis is a devastating infection caused predominantly by Aspergillus fumigatus. It occurs almost exclusively in severely immunocompromised patients — particularly those with prolonged neutropenia (hematologic malignancy, stem cell transplant), chronic granulomatous disease, or high-dose corticosteroid therapy.
Aspergillus — Angioinvasive Pathology
- Mechanism: Aspergillus hyphae are angioinvasive — they penetrate blood vessel walls, causing thrombosis, hemorrhagic infarction, and abscess formation
- Imaging: Hemorrhagic ring-enhancing lesions, often multiple; may cross the dura; hemorrhagic infarcts; MRI spectroscopy may show trehalose peak
- CSF: Often non-diagnostic; galactomannan antigen in CSF may be helpful but lacks sensitivity; serum galactomannan may be positive
- Brain biopsy: Often required for definitive diagnosis; shows septate hyphae with dichotomous (45-degree) branching on GMS or PAS stain
- Treatment: Voriconazole is first-line (superior to amphotericin B per landmark Herbrecht et al. trial); surgical resection for accessible abscesses; isavuconazole is an alternative
- Prognosis: Mortality >50–80% even with treatment; recovery of neutrophil count is the most important prognostic factor
Mucormycosis (Zygomycosis)
Mucormycosis (formerly zygomycosis) is caused by members of the order Mucorales, including Rhizopus, Mucor, and Rhizomucor species. The rhinocerebral form is the most relevant to neurologic practice and represents a true neurosurgical emergency.
Rhinocerebral Mucormycosis
- Classic setting: Diabetic ketoacidosis (DKA) — the acidotic, hyperglycemic environment favors fungal growth and impairs phagocytic function; also transplant recipients, neutropenia, deferoxamine therapy
- Progression pathway: Paranasal sinusitis → orbital invasion (proptosis, ophthalmoplegia, vision loss) → cavernous sinus thrombosis → cerebral invasion via contiguous spread or angioinvasion
- Clinical hallmark: Black eschar on nasal or palatal mucosa from tissue necrosis (not always present but highly suggestive)
- Imaging: Sinus opacification with bony erosion on CT; MRI shows sinus, orbital, and intracranial extension with enhancement; cavernous sinus involvement; brain abscess
- Diagnosis: Tissue biopsy is essential — shows broad, ribbon-like, pauci-septate hyphae with irregular (non-dichotomous) branching at right angles; cultures often negative despite positive histology
- Treatment: (1) Urgent and aggressive surgical debridement (often requiring repeated procedures); (2) IV amphotericin B (liposomal preferred, 5–10 mg/kg/day); (3) correction of underlying predisposition (DKA correction, immunosuppression reduction); isavuconazole and posaconazole are alternatives
- Mortality: 40–70% overall; approaches 100% without surgery; CNS involvement further worsens prognosis
| Feature | Aspergillosis | Mucormycosis |
|---|---|---|
| Hyphae morphology | Septate, dichotomous 45° branching | Pauci-septate, ribbon-like, right-angle branching |
| Classic host | Prolonged neutropenia, stem cell transplant | Diabetic ketoacidosis, iron overload |
| CNS entry | Hematogenous from pulmonary | Direct extension from sinuses |
| Key pathology | Hemorrhagic infarcts, abscesses | Tissue necrosis, angioinvasion, eschar |
| First-line treatment | Voriconazole | Amphotericin B + surgical debridement |
| Galactomannan | Positive (helpful diagnostic marker) | Negative (Mucorales do not produce galactomannan) |
Other Fungal CNS Infections
| Organism | Endemic Region | CNS Manifestation | Diagnosis | Treatment |
|---|---|---|---|---|
| Histoplasmosis | Ohio/Mississippi River valleys | Chronic meningitis, granulomas, myelopathy | CSF/urine Histoplasma antigen; CF antibodies; culture | Amphotericin B induction → itraconazole ≥1 year |
| Blastomycosis | Great Lakes, Ohio/Mississippi valleys | Brain abscess, meningitis (rare, <5%) | Culture; urine antigen (cross-reacts with Histoplasma) | Amphotericin B induction → azole maintenance |
| Candidiasis | Worldwide (nosocomial) | Meningitis (neonates, neurosurgery), microabscesses, ventriculitis | CSF culture; blood culture; beta-D-glucan | Amphotericin B ± flucytosine; remove hardware if present |
Parasitic CNS Infections
Neurocysticercosis
Neurocysticercosis (NCC), caused by the larval form of the pork tapeworm Taenia solium, is the most common parasitic infection of the CNS and the leading cause of acquired epilepsy worldwide. It is endemic in Latin America, sub-Saharan Africa, and South/Southeast Asia, but is increasingly encountered in non-endemic countries due to immigration.
Life Cycle and Pathogenesis
- Definitive host: Humans harbor the adult tapeworm in the intestine after ingesting undercooked pork containing cysticerci
- Intermediate host (disease-causing): Humans acquire cysticercosis by ingesting T. solium eggs (from contaminated food/water or fecal-oral transmission from a tapeworm carrier) — NOT from eating pork
- CNS invasion: Oncospheres hatch from ingested eggs, penetrate the intestinal wall, enter the bloodstream, and lodge in the CNS, forming cysticerci (fluid-filled cysts containing an invaginated scolex)
- Immune evasion: Viable cysts produce immune-modulatory factors, allowing them to persist for years without provoking an inflammatory response
- Degeneration and inflammation: When cysts begin to degenerate (spontaneously or after treatment), the host immune response produces perilesional edema and inflammation — this is when symptoms (seizures) typically occur
Stages of Cysticerci and Imaging
| Stage | Pathology | CT Appearance | MRI Appearance | Treatment Implication |
|---|---|---|---|---|
| Vesicular (viable) | Intact, fluid-filled cyst with living scolex | CSF-density cyst; scolex may be visible as eccentric nodule | CSF-signal cyst, no edema, scolex visible (pathognomonic "hole-with-dot" sign) | Antiparasitic therapy indicated (albendazole ± praziquantel) |
| Colloidal (degenerating) | Cyst degenerating with host inflammatory response | Ring or nodular enhancement, perilesional edema | Hyperintense cyst on FLAIR, surrounding edema, ring enhancement | Antiparasitic + corticosteroids (to control inflammation) |
| Granular-nodular | Retracting cyst, ongoing granulomatous response | Enhancing nodule, diminishing edema | Small enhancing nodule with decreasing surrounding signal | Antiparasitic benefit unclear; corticosteroids if symptomatic |
| Calcified (inactive) | Completely resolved cyst; residual calcification | Punctate calcification (classic finding on CT) | Low signal on all sequences; may be difficult to see (CT superior) | No antiparasitic therapy; AEDs if seizures; perilesional edema episodes can recur |
Clinical Presentations of Neurocysticercosis
Forms of Neurocysticercosis
- Parenchymal NCC (most common): Single or multiple intraparenchymal cysts; seizures are the presenting symptom in ~70% of cases; headache common; focal deficits depend on cyst location
- Ventricular NCC: Cysts within the ventricles can cause obstructive hydrocephalus (acute presentation); fourth ventricle most common location; may require neuroendoscopic removal
- Subarachnoid (racemose) NCC: Cysts in the subarachnoid space, especially basal cisterns; grow to large multilobulated ("grape-like") clusters; cause chronic basilar meningitis, hydrocephalus, cranial neuropathies, vasculitis with stroke; most treatment-refractory form
- Spinal NCC: Rare; intradural extramedullary or intramedullary cysts; myelopathy or radiculopathy
- Single enhancing lesion (SEL): The most common presentation in endemic countries; single degenerating cyst causing seizures; excellent prognosis; may resolve without antiparasitic therapy
Treatment of Neurocysticercosis
| Clinical Scenario | Antiparasitic Therapy | Corticosteroids | Additional Management |
|---|---|---|---|
| Viable parenchymal cysts (1–2) | Albendazole 15 mg/kg/day × 10–14 days | Dexamethasone during and briefly after treatment | AEDs for seizures; monitor with serial imaging |
| Viable parenchymal cysts (>2) | Albendazole + praziquantel (50 mg/kg/day) × 10–14 days | Dexamethasone essential (higher inflammatory risk) | Combined therapy superior to albendazole alone per RCTs |
| Single enhancing lesion | Short course albendazole (3–7 days) or observation | Short course if symptomatic | AEDs; often self-resolves; excellent prognosis |
| Calcified cysts only | NOT indicated | Short course for perilesional edema episodes | AEDs for seizure control; no role for antiparasitics |
| Ventricular cysts | Consider after surgical removal | Perioperative steroids | Neuroendoscopic excision preferred; VP shunt for hydrocephalus |
| Subarachnoid/racemose | Prolonged albendazole + praziquantel (months); guided by imaging and CSF | Prolonged corticosteroids or methotrexate for chronic inflammation | Most refractory form; VP shunt often needed; monitor for vasculitis/stroke |
Critical Precautions in NCC Treatment
- Always start corticosteroids before antiparasitics: Cyst death triggers inflammation that can worsen edema, seizures, and hydrocephalus; steroids should be started 1–2 days before albendazole
- Do NOT give antiparasitics for: Calcified-only disease (cysts are dead), cysticercotic encephalitis (massive cyst burden with diffuse edema — treat with steroids only first), or untreated obstructive hydrocephalus (surgical management first)
- Ophthalmologic examination: Rule out intraocular cysticerci before treatment — cyst death within the eye can cause irreversible vision loss
- Seizure management: AEDs should be started for all patients with seizures; duration of AED therapy depends on seizure recurrence risk and lesion resolution
Cerebral Malaria
Cerebral malaria is the most severe neurologic complication of Plasmodium falciparum infection and represents a medical emergency with mortality rates of 15–25% even with treatment.
Cerebral Malaria — Key Features
- Definition: P. falciparum parasitemia with altered consciousness (GCS ≤11 in adults, Blantyre Coma Scale ≤2 in children) after excluding other causes of encephalopathy
- Pathophysiology: Parasitized erythrocytes sequester in cerebral microvasculature via adhesion to endothelial receptors (PfEMP1 binding to ICAM-1, EPCR); this produces microvascular obstruction, blood-brain barrier disruption, inflammation, and metabolic derangement
- Clinical features: High fever, altered consciousness progressing to coma, generalized seizures (especially in children), retinal changes (white-centered hemorrhages, papilledema, vessel whitening — "malarial retinopathy" is >95% specific), brainstem signs in severe cases
- Diagnosis: Peripheral blood smear showing ring-form trophozoites; rapid diagnostic tests (HRP2-based); parasitemia level (often >5%); lactic acidosis, hypoglycemia, anemia
- Treatment: IV artesunate (2.4 mg/kg at 0, 12, 24 hours, then daily) — superior to IV quinine per SEAQUAMAT and AQUAMAT trials; supportive care including seizure management, glucose monitoring, fluid resuscitation
- Neurologic sequelae: ~10–25% of survivors (especially children) have persistent deficits including epilepsy, cognitive impairment, motor deficits, cortical blindness, behavioral changes
Toxoplasmosis
CNS toxoplasmosis, caused by Toxoplasma gondii, is the most common opportunistic CNS infection in HIV/AIDS (typically CD4 <100 cells/μL). It produces ring-enhancing lesions with a predilection for the basal ganglia and corticomedullary junction. Presentation includes headache, confusion, fever, focal deficits, and seizures. Diagnosis is typically presumptive based on imaging pattern, positive Toxoplasma serology (IgG), and clinical response to empiric therapy. Treatment is pyrimethamine + sulfadiazine + leucovorin for at least 6 weeks. If no improvement in 10–14 days, brain biopsy should be considered to exclude CNS lymphoma.
Primary Amebic Meningoencephalitis (PAM)
Naegleria fowleri — Fulminant Meningitis
- Organism: Naegleria fowleri, a free-living ameba found in warm freshwater (lakes, hot springs, poorly maintained swimming pools, neti pots with tap water)
- Transmission: Enters through the nasal mucosa, travels along olfactory nerves to the brain — NOT from ingestion of contaminated water
- Presentation: Fulminant, rapidly progressive meningoencephalitis — severe headache, fever, nausea/vomiting, altered consciousness, seizures; onset 1–9 days after freshwater exposure; progresses to death within 3–7 days
- CSF: Hemorrhagic or purulent; elevated WBC (predominantly neutrophils); elevated protein; low glucose; motile trophozoites may be seen on wet mount (often mistaken for WBCs)
- Diagnosis: Motile amebae on CSF wet mount; CSF PCR for Naegleria; high index of suspicion in any fulminant meningitis with freshwater exposure history
- Treatment: IV amphotericin B, miltefosine, fluconazole, azithromycin, rifampin — multi-drug approach; despite treatment, mortality >95%; rare survivors reported with early aggressive therapy and therapeutic hypothermia
- Key teaching point: Always ask about recent freshwater exposure in fulminant meningitis cases, especially during summer months
Other Parasitic CNS Infections
| Organism | Geographic Distribution | CNS Manifestation | Diagnosis | Treatment |
|---|---|---|---|---|
| Trypanosoma brucei (African sleeping sickness) | Sub-Saharan Africa (tsetse fly) | Stage 2: meningoencephalitis with sleep-wake cycle disruption, behavioral changes, coma | CSF trypanosomes; elevated IgM; Morular (Mott) cells | Fexinidazole (oral, first-line stage 2 T. b. gambiense); nifurtimox-eflornithine (NECT) |
| Angiostrongylus cantonensis | Southeast Asia, Pacific Islands, Caribbean | Eosinophilic meningitis (most common cause worldwide) | CSF eosinophilia; exposure history (raw snails/slugs); serology/PCR | Supportive; corticosteroids for inflammation; self-limited in most |
| Echinococcus (hydatid disease) | Worldwide (sheep-raising areas) | Cerebral hydatid cysts (rare, ~2% of cases); mass lesion mimicking tumor | Imaging (cystic lesion); serology | Surgical resection (intact removal preferred); albendazole perioperatively |
| Schistosoma | Africa, Asia, South America | S. japonicum: cerebral granulomas, seizures; S. mansoni: spinal cord (conus/cauda equina) | Serology; egg morphology on biopsy; MRI findings | Praziquantel + corticosteroids |
| Strongyloides stercoralis | Tropical/subtropical; hyperinfection worldwide | Hyperinfection syndrome with gram-negative meningitis (larvae carry gut bacteria to CNS) | Larvae in stool/sputum; serology; gram-negative meningitis in immunosuppressed | Ivermectin; treat gram-negative meningitis; reduce immunosuppression |
Diagnostic Approach to Suspected Fungal or Parasitic CNS Infection
Key Principles in the Diagnostic Workup
- History is paramount: Geographic exposure (travel, residence in endemic areas), immigration history, freshwater exposure, animal contacts, dietary habits (raw pork, snails), immunosuppression type and duration
- CSF analysis: Cell count with differential (eosinophils suggest parasitic or coccidioidal infection), protein, glucose, opening pressure, CrAg, specific antibodies, PCR, cytology, culture
- Serum markers: CrAg, beta-D-glucan (pan-fungal but not useful for Mucorales or Cryptococcus), galactomannan (Aspergillus), specific serologies (Coccidioides CF, Toxoplasma IgG)
- Imaging patterns: Ring-enhancing lesions (toxoplasmosis, abscess), basilar meningeal enhancement (Coccidioides, TB), hemorrhagic lesions (Aspergillus), cysts with scolex (NCC), hydrocephalus (multiple etiologies)
- Tissue diagnosis: Brain biopsy when non-invasive testing is non-diagnostic; essential for Aspergillus and Mucor confirmation; stereotactic biopsy preferred for deep lesions
- Multidisciplinary approach: Involve infectious disease, neurosurgery, neuroradiology, and pathology early in the workup of suspected fungal/parasitic CNS infections
References
- Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291-322.
- Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-2498.
- Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63(6):e112-e146.
- Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-415.
- Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-569.
- Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol. 2014;13(12):1202-1215.
- Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14(8):687-695.
- White NJ, Turner GD, Day NP, et al. Lethal malaria: Marchiafava and Bignami were right. J Infect Dis. 2013;208(2):192-198.
- Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647-1657.
- Del Brutto OH, Nash TE, White AC Jr, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017;372:202-210.
- Rajshekhar V, Joshi DD, Doanh NQ, et al. Taenia solium taeniosis/cysticercosis in Asia: epidemiology, impact and issues for control. Acta Trop. 2003;87(1):53-60.
- Cope JR, Ali IK. Primary amebic meningoencephalitis: what have we learned in the last 5 years? Curr Infect Dis Rep. 2016;18(10):31.
- Wang Q, Bao L, Wang J, et al. Cryptococcal meningitis: a review of diagnostic methods and therapeutic management. Mycoses. 2023;66(1):e13667.
- Nash TE, Mahanty S, Garcia HH. Corticosteroid use in neurocysticercosis. Expert Rev Neurother. 2011;11(8):1175-1183.
- Wheat LJ, Batteiger BE, Sathapatayavongs B. Histoplasma capsulatum infections of the central nervous system. Medicine (Baltimore). 1990;69(4):244-260.